comprehensive -WSS

comprehensive

author：fashion 2025-09-04 22:14:57 - browse：7899

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Princess Kate attends Wimbledon with Roger Federer: See the photos

WSS

The biotech scorecard for Q4: 16 stock

Medicare innovation center doesn’t save money, experts say

RSV injection headlines need to be accurate for good uptake

Myanmar's Supreme Court hears arguments in 2 appeals by ousted leader Aung San Suu Kyi

Pope Francis asks Church to identify 21st

Former New York Mayor de Blasio and wife announce separation, but not divorce

Wikipedia

comprehensive

leisure time

Virginia high school admissions case could be legal follow

The leaders of Italy and Poland say European Union should focus on stopping migration

Guidelines to prevent youth baseball injuries need more muscle

EU moves toward latest gene techniques in food production to counter climate change, shortages

Jerome Adams on the need for new antivirals for Covid

Setback for rare diseases as Taysha Gene Therapies pulls back

Peter Hotez and the public health issue of online harassment

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Guidelines to prevent youth baseball injuries need more muscle

Israel withdraws forces after 2

explore

Pope Francis asks Church to identify 21st

2 million sign

China dismisses criticism of top diplomat's comments appearing to push for race

New oral drug delivery patch is modeled after octopus tentacles

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Health insurers' Q3 question: how much care are people getting?

explore

entertainment

explore

focus